Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen; Sanna-Kaisa Herukka; Niels Andreasen; Ines Baldeiras; Maria Bjerke; Kaj Blennow; Sebastiaan Engelborghs; Giovanni B Frisoni; Tomasz Gabryelewicz; Samantha Galluzzi; Ron Handels; Milica G Kramberger; Agnieszka Kulczyńska; Jose Luis Molinuevo; Barbara Mroczko; Agneta Nordberg; Catarina Resende Oliveira; Markus Otto; Juha O Rinne; Uroš Rot; Esen Saka; Hilkka Soininen; Hanne Struyfs; Silvia Suardi; Pieter Jelle Visser; Bengt Winblad; Henrik Zetterberg; Gunhild Waldemar

doi:10.1016/j.jalz.2016.09.008

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O Rinne, Uroš RotEsen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar

Centro San Giovanni di Dio - Fatebenefratelli

Research output: Contribution to journal › Review article › peer-review

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

Original language	English
Pages (from-to)	274-284
Number of pages	11
Journal	Alzheimer's and Dementia
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2016.09.008
Publication status	Published - Mar 2017

Keywords

Alzheimer Disease
Amyloid beta-Peptides
Biomarkers
Databases, Bibliographic
Humans
Peptide Fragments
tau Proteins
Journal Article
Review

Access to Document

10.1016/j.jalz.2016.09.008

Cite this

Simonsen, A. H., Herukka, S-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., Handels, R., Kramberger, M. G., Kulczyńska, A., Molinuevo, J. L., Mroczko, B., Nordberg, A., Oliveira, C. R., Otto, M., Rinne, J. O., ... Waldemar, G. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 13(3), 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

Simonsen, AH, Herukka, S-K, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, Engelborghs, S, Frisoni, GB, Gabryelewicz, T, Galluzzi, S, Handels, R, Kramberger, MG, Kulczyńska, A, Molinuevo, JL, Mroczko, B, Nordberg, A, Oliveira, CR, Otto, M, Rinne, JO, Rot, U, Saka, E, Soininen, H, Struyfs, H, Suardi, S, Visser, PJ, Winblad, B, Zetterberg, H & Waldemar, G 2017, 'Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia', Alzheimer's and Dementia, vol. 13, no. 3, pp. 274-284. https://doi.org/10.1016/j.jalz.2016.09.008

@article{fe8d287f57dd4360a92c38593f2f8cf6,

title = "Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia",

abstract = "This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.",

keywords = "Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Databases, Bibliographic, Humans, Peptide Fragments, tau Proteins, Journal Article, Review",

author = "Simonsen, {Anja Hviid} and Sanna-Kaisa Herukka and Niels Andreasen and Ines Baldeiras and Maria Bjerke and Kaj Blennow and Sebastiaan Engelborghs and Frisoni, {Giovanni B} and Tomasz Gabryelewicz and Samantha Galluzzi and Ron Handels and Kramberger, {Milica G} and Agnieszka Kulczy{\'n}ska and Molinuevo, {Jose Luis} and Barbara Mroczko and Agneta Nordberg and Oliveira, {Catarina Resende} and Markus Otto and Rinne, {Juha O} and Uro{\v s} Rot and Esen Saka and Hilkka Soininen and Hanne Struyfs and Silvia Suardi and Visser, {Pieter Jelle} and Bengt Winblad and Henrik Zetterberg and Gunhild Waldemar",

year = "2017",

month = mar,

doi = "10.1016/j.jalz.2016.09.008",

language = "English",

volume = "13",

pages = "274--284",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

AU - Simonsen, Anja Hviid

AU - Herukka, Sanna-Kaisa

AU - Andreasen, Niels

AU - Baldeiras, Ines

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B

AU - Gabryelewicz, Tomasz

AU - Galluzzi, Samantha

AU - Handels, Ron

AU - Kramberger, Milica G

AU - Kulczyńska, Agnieszka

AU - Molinuevo, Jose Luis

AU - Mroczko, Barbara

AU - Nordberg, Agneta

AU - Oliveira, Catarina Resende

AU - Otto, Markus

AU - Rinne, Juha O

AU - Rot, Uroš

AU - Saka, Esen

AU - Soininen, Hilkka

AU - Struyfs, Hanne

AU - Suardi, Silvia

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Waldemar, Gunhild

PY - 2017/3

Y1 - 2017/3

N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.

KW - Alzheimer Disease

KW - Amyloid beta-Peptides

KW - Biomarkers

KW - Databases, Bibliographic

KW - Humans

KW - Peptide Fragments

KW - tau Proteins

KW - Journal Article

KW - Review

U2 - 10.1016/j.jalz.2016.09.008

DO - 10.1016/j.jalz.2016.09.008

M3 - Review article

C2 - 28341065

VL - 13

SP - 274

EP - 284

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

Abstract

Keywords

Access to Document

Fingerprint

Cite this